Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1056/NEJMc1105515 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
EARLY NONINVASIVE EVALUATION OF LIVER FIBROSIS AFTER HEPATITIS C TREATMENT: THE IMPACT OF INFLAMMATION.
Arq Gastroenterol
January 2025
Universidade Federal de São Paulo, São Paulo, SP, Brasil.
Background: Liver biopsy (LB) is still the gold standard method for assessing hepatic fibrosis (HF), associated diseases, and liver inflammation. Nowadays, noninvasive techniques such as Acoustic radiation force impulse (ARFI) elastography have been introduced instead of liver biopsy. However, there are controversies about the time it should be performed after treatment for hepatitis C virus (HCV).
View Article and Find Full Text PDFSubstitutions in SARS-CoV-2 Mpro Selected by Protease Inhibitor Boceprevir Confer Resistance to Nirmatrelvir.
Viruses
September 2023
Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital-Hvidovre, Kettegård Alle 30, 2650 Hvidovre, Denmark.
Nirmatrelvir, which targets the SARS-CoV-2 main protease (Mpro), is the first-in-line drug for prevention and treatment of severe COVID-19, and additional Mpro inhibitors are in development. However, the risk of resistance development threatens the future efficacy of such direct-acting antivirals. To gain knowledge on viral correlates of resistance to Mpro inhibitors, we selected resistant SARS-CoV-2 under treatment with the nirmatrelvir-related protease inhibitor boceprevir.
View Article and Find Full Text PDFClinical and economic value of sofosbuvir-based regimens in the treatment of chronic hepatitis C in Spain.
PLoS One
December 2022
Pharmacoeconomics & Outcomes Research Iberia (PORIB), Madrid, Spain.
Article Synopsis
- - The study evaluated the effectiveness of Sofosbuvir (SOF)-based treatments for chronic hepatitis C in Spain from 2015-2019, showing improved patient outcomes compared to older therapies like peginterferon and ribavirin.
- - SOF-based regimens yielded a sustained virological response (SVR) of 93-98% and significantly reduced complications such as decompensated cirrhosis (by 89%) and liver-related mortality (by 82%), while also providing substantial cost savings.
- - Overall, the findings support SOF-based treatments as a cost-effective solution that enhances health outcomes for HCV patients in Spain, aligning with global health objectives set by the WHO.
Effect of Sofosbuvir/Ledipasvir and Glecaprevir/Pibrentasvir on Serum Creatinine.
J Clin Exp Hepatol
August 2021
Institute of Digestive Heath and Liver Diseases, Mercy Medical Center, Baltimore, MD, USA.
Background & Objectives: There are reports of worsening renal functions with sofosbuvir, but there are no comparative data of different direct-acting antivirals (DAAs) on serum creatinine. In this retrospective cohort analysis, we examined the treatment effect of two commonly used regimens, sofosbuvir/ledipasvir (SOF/LDV) and glecaprevir/pibrentasvir (GLE/PIB), on serum creatinine.
Methods: We included all patients treated with SOF/LDV (n = 825) and GLE/PIB (n = 116) between December 1, 2014, and December 31, 2018.
Adoption of new therapies in the treatment of Hepatitis: a verification of the accuracy of budget impact analysis to guide investment decisions.
Expert Rev Pharmacoecon Outcomes Res
September 2022
Department of Social Pharmacy, Faculty of Pharmacy, Federal University of Minas Gerais. Belo Horizonte, Minas Gerais, Brazil.
Objectives: While there are good Budget Impact Analysis (BIA) guidelines, studies still register potential bias. To do this, we compared the results between theoretical and real-world evidence (RWE) expenditures for medicines for Hepatitis C: boceprevir (BOC) and telaprevir (TVR). While both are not currently recommended in treatment guidelines following recent developments, this is an emblematic case because for 4 years these medicines consumed considerable resources.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!